Selumetinib (sulfate)

Selumetinib (sulfate)

• CAS Number: 943332-08-9
• UNSPSC Description: Selumetinib (AZD6244) is selective, non-ATP-competitive oral?MEK1/2?inhibitor, with an IC50 of 14 nM for MEK1. Selumetinib (AZD6244) inhibits ERK1/2 phosphorylation.
• Target Antigen: Apoptosis; MEK
• Type: Reference compound
• Related Pathways: Apoptosis;MAPK/ERK Pathway
• Applications: Neuroscience-Neurodegeneration
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/selumetinib-sulfate.html
• Purity: 99.58
• Solubility: DMSO : 50 mg/mL (ultrasonic)|H2O : < 0.1 mg/mL
• Smiles: OCCONC(C(C=C1C(N=CN1C)=C2F)=C2NC3=C(C=C(Br)C=C3)Cl)=O.O=S(O)(O)=O
• Molecular Weight: 555.76
• References & Citations: [1][1].Huynh H, et al, Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma. Mol Cancer Therapy, 2007, 6 (1), 138-146|[2][2].Garon EB, et al. Identification of common predictive markers of in vitro response to the Mek inhibitor selumetinib (AZD6244; ARRY-142886) in human breast cancer and non-small cell lung cancer cell lines. Mol Cancer Thera, 2010, 9 (7), 1985-1994.|[3][3].Yeh TC, et al. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin Cancer Res, 2007, 13 (5), 1576-1583.
• Shipping Conditions: Room Temperature
• Storage Conditions: 4°C (Powder, sealed storage, away from moisture)
• Clinical Information: Launched